Remdesivir-associated bradycardia.

Ching, Patrick R; Lee, Calvin

Ching, Patrick R; Lee, Calvin.

Ching PR; Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA patrickrching@gmail.com.
Lee C; Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

BMJ Case Rep ; 14(9)2021 Sep 03.

Article in English | MEDLINE | ID: covidwho-1467680

ABSTRACT

ABSTRACT

Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using ß-blockers.

Subject(s)

Bradycardia; COVID-19 Drug Treatment; Adenosine Monophosphate/analogs & derivatives; Adult; Aged; Alanine/analogs & derivatives; Antiviral Agents/therapeutic use; Bradycardia/chemically induced; Bradycardia/drug therapy; Humans; Male; SARS-CoV-2

Keywords

COVID-19; cardiovascular medicine; drugs and medicines; infectious diseases

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bradycardia / COVID-19 Drug Treatment Type of study: Case report Limits: Adult / Aged / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: BCR-2021-245289

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google